Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan 24:11:815213.
doi: 10.3389/fonc.2021.815213. eCollection 2021.

A Comparative Study on the Accuracy and Efficacy Between Dalton and CINtec® PLUS p16/Ki-67 Dual Stain in Triaging HPV-Positive Women

Affiliations
Free PMC article

A Comparative Study on the Accuracy and Efficacy Between Dalton and CINtec® PLUS p16/Ki-67 Dual Stain in Triaging HPV-Positive Women

Ying Li et al. Front Oncol. .
Free PMC article

Abstract

Background: CINtec® PLUS p16/Ki-67 dual-stained cytology (DS) is an alternative test to cytology in triaging human papillomavirus (HPV)-positive women. Dalton p16/Ki-67 Dual Stain kit employs the similar immunocytochemical detection and operating procedures with CINtec® PLUS, but its accuracy and efficacy in triaging HPV-positive women need to be evaluated.

Methods: A total of 717 HPV-positive specimens of cervical exfoliated cells were included. Cytology, Dalton, and CINtec® PLUS were subsequently performed, and two DS tests were separately completed in each of the same specimens. The results of two DS tests were head-to-head compared, and their efficacies to identify high-grade cervical intraepithelial neoplasia (CIN) were evaluated, using histopathology of biopsy as the golden standard.

Results: The overall positive rate of two DS tests were 28.31% for Dalton and 33.89% for CINtec® PLUS (p < 0.05); both rose with the increased severity of histopathological and cytological abnormalities. Compared to CINtec® PLUS, the positive rate of Dalton was significantly lower in the normal histopathology group (p < 0.05) and lower, but not significantly, in mild abnormal histopathology and cytology NILM and LSIL groups. Two DS tests showed a good consistency (Kappa value, 0.63; 95% CI, 0.557-0.688), with 100% of consistency in the cytology HSIL group. Inconsistency occurred mainly in the cytology NILM and LSIL groups, with more Dalton negative but CINtec® PLUS positive. Compared to CINtec® PLUS, Dalton showed similar sensitivity (94.59% vs. 91.89%), but significantly higher specificity (75.29% vs. 69.26%, p = 0.013) and accuracy (76.29% vs. 70.43%, p = 0.012), with a larger area under the curve (AUC) of 0.849 (95% CI, 0.800-0.899) for identifying CIN3+. The similar results were observed when identifying CIN2+.

Conclusions: Dalton presents the lower false positive rate and better efficacy in identifying high-grade CIN than CINtec® PLUS, suggesting that Dalton may be superior to CINtec® PLUS and an alternative technique for triaging primary HPV-positive women in cervical cancer screening.

Keywords: cervical cancer; cervical cancer screening; cervical intraepithelial neoplasia; human papillomavirus; p16/Ki-67 dual stain.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Figures

Figure 1
Figure 1
Flowchart of subject recruitment. HPV, human papillomavirus; NILM, negative for intraepithelial lesion or malignancy; ASC-US, atypical squamous cells of undetermined significance; LSIL, low-grade squamous intraepithelial lesion; ASC-H, atypical squamous cells, cannot rule out high-grade squamous intraepithelial lesion; HSIL, high-grade squamous intraepithelial lesions. aIncluded 3 of SCC (squamous cell carcinoma), 1 of AC (adenocarcinoma) and 1 of AGC-NOS (atypical glandular cell of undetermined significance).
Figure 2
Figure 2
Representative photos of p16/Ki-67 dual stain cytology. Cervical exfoliated cells negative (A) and positive (B) for for Dalton, negative (C), and positive (D) for CINtec® PLUS, respectively. The brown cytoplasm/nuclear signal showed p16 staining alone, and the red nuclear signal showed Ki-67 staining alone. The positive p16/Ki-67 dual stain cell had both brown and red signal, which reflected the colocalization of p16 and Ki-67 in the same cell.
Figure 3
Figure 3
ROC curve analysis of Dalton and CINtec® PLUS in detecting CIN3+ (A) and CIN2+ (B). (A) The AUC were 0.849 (95% CI, 0.800-0.899) for Dalton and 0.806 (95% CI, 0.747-0.865) for CINtec® PLUS. (B) The AUC were 0.833 (95% CI, 0.787-0.879) for Dalton and 0.802 (95% CI, 0.754-0.849) for CINtec® PLUS. ROC, receiver operating characteristic; CIN3+, cervical intraepithelial neoplasia grade 3 or worse; CIN2+, cervical intraepithelial neoplasia grade 2 or worse; AUC, area under the curve.

Similar articles

Cited by

References

    1. Global Burden of Disease Cancer C. Fitzmaurice C, Abate D, Abbasi N, Abbastabar H, Abd-Allah F, et al. . Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017: A Systematic Analysis for the Global Burden of Disease Study. JAMA Oncol (2019) 5(12):1749–68. doi: 10.1001/jamaoncol.2019.2996 - DOI - PMC - PubMed
    1. Wentzensen N, Arbyn M, Berkhof J, Bower M, Canfell K, Einstein M, et al. . Eurogin 2016 Roadmap: How HPV Knowledge Is Changing Screening Practice. Int J Cancer (2017) 140(10):2192–200. doi: 10.1002/ijc.30579 - DOI - PubMed
    1. Fontham ETH, Wolf AMD, Church TR, Etzioni R, Flowers CR, Herzig A, et al. . Cervical Cancer Screening for Individuals at Average Risk: 2020 Guideline Update From the American Cancer Society. CA Cancer J Clin (2020) 70(5):321–46. doi: 10.3322/caac.21628 - DOI - PubMed
    1. Huh WK, Ault KA, Chelmow D, Davey DD, Goulart RA, Garcia FAR, et al. . Use of Primary High-Risk Human Papillomavirus Testing for Cervical Cancer Screening: Interim Clinical Guidance. Obstet Gynecol (2015) 125(2):330–37. doi: 10.1097/AOG.0000000000000669 - DOI - PubMed
    1. Kyrgiou M, Arbyn M, Bergeron C, Bosch FX, Dillner J, Jit M, et al. . Cervical Screening: ESGO-EFC Position Paper of the European Society of Gynaecologic Oncology (ESGO) and the European Federation of Colposcopy (EFC). Br J Cancer (2020) 123(4):510–17. doi: 10.1038/s41416-020-0920-9 - DOI - PMC - PubMed

LinkOut - more resources